Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Prostate Cancer treatment details. Biologic therapy. Chemotherapy. National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States



Survival: 28.9 months
   
Toxicity Grade: 3
   
Treatments: Biologic therapy
Chemotherapy
   
Drugs: Taxotere
Thalomid
Country: United States
   
City/State/Province: Bethesda, Maryland
   
Hospital: National Cancer Institute, National Institutes of Health
   
Journal: Link
   
Date: 7/2004

Description:
Patients: This Phase II trial involved a total of 75 patients with hormone refractory (androgen-independent) prostate cancer. Patients were divided into two groups: Group 1 comprised of 25 patients and Group 2 comprised of 50 patients. The median age for patients in Group 2 was 71 years and the median baseline PSA was 59.9 (range 2 1,777).

Treatment: For patients in Group 2, the treatment consisted of the chemotherapy drug, docetaxel (taxotere) plus the anti-angiogenesis drug, thalidomide (thalomid).

Toxicity: For patients in Group 2, grade 3 toxicities included fatigue, allergic reaction, depression, thrombosis, hyperglycemia, thrombocytopenia, neutropenia, and anemia.

Results: For patients in Group 2 the median survival was 28.9 months.

Correspondence: William D. Figg, MD

E-mail to a Friend Email Physician More Information